Amgen drops Phase 1 obesity candidate AMG-513 after FDA partial hold. MariTide remains its obesity focus.
Amgen is cutting its secretive early-stage obesity candidate, AMG-513.
The company hasn’t revealed much about the Phase 1 program or why it’s being discontinued. When …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.
AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B…
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new…
Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer.
Retatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval…
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron…
